2-[[(2R)-1-[1-[(4-chloro-3-methylphenyl)methyl]piperidin-4-yl]-5-oxopyrrolidine-2-carbonyl]amino]-N-(cyclopropylmethyl)-6-methylpyridine-4-carboxamide | 1372126-73-2

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 哌啶类
• 英文名称: 2-[[(2R)-1-[1-[(4-chloro-3-methylphenyl)methyl]piperidin-4-yl]-5-oxopyrrolidine-2-carbonyl]amino]-N-(cyclopropylmethyl)-6-methylpyridine-4-carboxamide
• CAS: 1372126-73-2
• 化学式: C₂₉H₃₆ClN₅O₃
• 分子量: 538.09
• InChiKey: OUGOQNYEXLDDNI-RUZDIDTESA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.5
• 重原子数：
  38
• 可旋转键数：
  8
• 环数：
  5.0
• sp3杂化的碳原子比例：
  0.52
• 拓扑面积：
  94.6
• 氢给体数：
  2
• 氢受体数：
  5

文献信息

• PROCESS FOR THE MANUFACTURING OF CRR INHIBITORS
  申请人：DURAN Adil

  公开号：US20130261307A1

  公开（公告）日：2013-10-03

  The present invention relates to a process for preparing CCR3 inhibitors of formula 1, wherein R 1 is H, C 1-6 -alkyl, C 0-4 -alkyl-C 3-6 -cycloalkyl, C 1-6 -haloalkyl; R 2 is H, C 1-6 -alkyl; X is an anion selected from the group consisting of chloride or ½ dibenzoyltartrate j is 1 or 2.

  本发明涉及一种制备公式1中CCR3抑制剂的方法，其中R1为H，C1-6-烷基，C0-4-烷基-C3-6环烷基，C1-6卤代烷基；R2为H，C1-6烷基；X为从氯化物或1/2苯甲酰酒石酸盐中选择的阴离子；j为1或2。
• [EN] PROCESS FOR THE MANUFACTURING OF CCR3 INHIBITORS<br/>[FR] PROCÉDÉ DE FABRICATION D'INHIBITEURS DE CCR3
  申请人：BOEHRINGER INGELHEIM INT

  公开号：WO2013149926A1

  公开（公告）日：2013-10-10

  The present invention relates to a process for preparing CCR3 inhibitors of formula (1), wherein R1 is H, C1-6-alkyl, C0-4-alkyl-C3-6-cycloalkyl, C1-6-haloalkyl; R2 is H, C1-6-alkyl; Xis an anion selected from the group consisting of chloride or ½ dibenzoyltartrate; j is 1 or 2.

  本发明涉及一种制备式（1）的CCR3抑制剂的方法，其中R1为H，C1-6-烷基，C0-4-烷基-C3-6-环烷基，C1-6-卤代烷基；R2为H，C1-6-烷基；X为氯离子或1/2苯二甲酰酒石酸根离子中选择的一种；j为1或2。
• CO-CRYSTALS AND SALTS OF CCR3-INHIBITORS
  申请人：Frank Markus

  公开号：US20120264729A1

  公开（公告）日：2012-10-18

  This invention relates to co-crystals and salts of CCR3 inhibitors of formula 1, pharmaceutical compositions containing the same, and methods of using the same as agents for treatment and/or prevention of diseases related with the CCR3-receptor.

  本发明涉及公式1的CCR3抑制剂的共晶体和盐，包含相同物质的药物组合物，以及将其用作治疗和/或预防与CCR3受体相关疾病的药剂的方法。
• [EN] CO-CRYSTALS AND SALTS OF CCR3-INHIBITORS<br/>[FR] CO-CRISTAUX ET SELS D'INHIBITEURS DE CCR3
  申请人：BOEHRINGER INGELHEIM INT

  公开号：WO2012045803A1

  公开（公告）日：2012-04-12

  This invention relates to co-crystals and salts of CCR3 inhibitors of formula (1), pharmaceutical compositions containing the same, and methods of using the same as agents for treatment and/or prevention of diseases related with the CCR3-receptor.

  本发明涉及公式（1）的CCR3抑制剂的共晶体和盐、包含它们的制药组合物，以及将它们用作治疗和/或预防与CCR3受体相关疾病的药物的方法。
• PHARMACEUTICAL FORMULATIONS COMPRISING CCR3 ANTAGONISTS
  申请人：Alkahest, Inc.

  公开号：EP3524230A1

  公开（公告）日：2019-08-14

  The present invention relates to pharmaceutical compositions containing compounds of formula 1 wherein R1 is H, C1-6-alkyl, C0-4-alkyl-C3-6-cycloalkyl, C1-6-haloalkyl; R2 is H, C1-6-alkyl; X is an anion selected from the group consisting of chloride or ½ dibenzoyltartrate j is 1 or 2. processes for the preparation thereof, and their use to treat diseases connected with the CCR3 receptor

  本发明涉及含有式 1 化合物的药物组合物 其中 R1 是 H、C1-6-烷基、C0-4-烷基-C3-6-环烷基、C1-6-卤代烷基； R2 是 H、C1-6-烷基； X 是选自氯化物或 1/2 二苯甲酰酒石酸盐的阴离子 j 为 1 或 2。 其制备工艺及其用于治疗与 CCR3 受体有关的疾病的用途